Orbit Genomics is transforming cancer diagnosis, treatment and prevention through early warning genomics. Our patent-pending OrbiSeq platform analyzes novel markers which uniquely reflect inherited disease risk and risk acquired from living. OrbiSeq-L is a diagnostic test for lung cancer to confirm positive low-dose CT (LDCT) with indeterminate nodules. The prototype test demonstrated an unparalleled 92%PPV and 97%NPV in a published study.